FDA Advisory Panel To Vote On Alzheimer’s Drug; ICER To Assess Price

An FDA advisory committee will vote Nov. 6 on whether to recommend that FDA approve the first drug to treat Alzheimer’s, and the Institute for Clinical and Economic Review already is planning the process of recommending a price for what might be a very expensive drug. Given the shift in the drug industry to basing prices on their savings to the health care system, the approval of an Alzheimer’s treatment could fan the flames of the debate over drug prices...